BRIEF-Cocrystal Pharma Enrollment Completed In Phase 2A Study With Oral Antiviral Candidate CC-42344

Reuters05-01

May 1 (Reuters) - Cocrystal Pharma Inc :

* COCRYSTAL PHARMA INC: ENROLLMENT COMPLETED IN PHASE 2A STUDY WITH ORAL ANTIVIRAL CANDIDATE CC-42344 FOR PANDEMIC AND SEASONAL INFLUENZA

* COCRYSTAL PHARMA: PLANS PHASE 1 STUDY IN AUSTRALIA WITH INHALED FORMULATION OF CC-42344 AS POTENTIAL INFLUENZA A TREATMENT & POST-EXPOSURE PROPHYLAXIS

Source text for Eikon: Further company coverage:

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2432831576?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-05-01 20:31","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2432831576","market":"us","top_or_hot":-1,"title":"BRIEF-Cocrystal Pharma Enrollment Completed In Phase 2A Study With Oral Antiviral Candidate CC-42344","media":"Reuters","content":"<html><body><p>May 1 (Reuters) - Cocrystal Pharma Inc   :</p><p>   * COCRYSTAL PHARMA INC: ENROLLMENT COMPLETED IN PHASE 2A STUDY WITH ORAL ANTIVIRAL CANDIDATE CC-42344 FOR PANDEMIC AND SEASONAL INFLUENZA</p><p>   * COCRYSTAL PHARMA: PLANS PHASE 1 STUDY IN AUSTRALIA WITH INHALED FORMULATION OF CC-42344 AS POTENTIAL INFLUENZA A TREATMENT &amp; POST-EXPOSURE PROPHYLAXIS</p><p>Source text for Eikon:    Further company coverage:   </p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-Cocrystal Pharma Enrollment Completed In Phase 2A Study With Oral Antiviral Candidate CC-42344</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-Cocrystal Pharma Enrollment Completed In Phase 2A Study With Oral Antiviral Candidate CC-42344\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-05-01 20:31 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1><strong>Reuters</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>May 1 (Reuters) - Cocrystal Pharma Inc   :   * COCRYSTAL PHARMA INC: ENROLLMENT COMPLETED IN PHASE 2A STUDY WITH ORAL ANTIVIRAL CANDIDATE CC-42344 FOR PANDEMIC AND SEASONAL INFLUENZA   * COCRYSTAL ...</p>\n\n<a href=\"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4007","symbol_name":"制药","start_time":0,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","article_id":"2432831576","we_media_id":"1036604489","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2432831576","pubTimestamp":1714566713,"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"summary":"May 1  - Cocrystal Pharma Inc   :   * COCRYSTAL PHARMA INC: ENROLLMENT COMPLETED IN PHASE 2A STUDY WITH ORAL ANTIVIRAL CANDIDATE CC-42344 FOR PANDEMIC AND SEASONAL INFLUENZA   * COCRYSTAL PHARMA: PLANS PHASE 1 STUDY IN AUSTRALIA WITH INHALED FORMULATION OF CC-42344 AS POTENTIAL INFLUENZA A TREATMENT & POST-EXPOSURE PROPHYLAXISSource text for Eikon:    Further company coverage:    ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4007":"制药","BK4098":"多种化学制品","COCP":"Cocrystal Pharma, Inc.","CC":"Chemours Company"},"translate_title":"简介-Cocrystal Pharma在口服抗病毒候选药物CC-42344的2A期研究中完成招募","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CC":1,"COCP":0.9},"content_text":"May 1 (Reuters) - Cocrystal Pharma Inc   :   * COCRYSTAL PHARMA INC: ENROLLMENT COMPLETED IN PHASE 2A STUDY WITH ORAL ANTIVIRAL CANDIDATE CC-42344 FOR PANDEMIC AND SEASONAL INFLUENZA   * COCRYSTAL PHARMA: PLANS PHASE 1 STUDY IN AUSTRALIA WITH INHALED FORMULATION OF CC-42344 AS POTENTIAL INFLUENZA A TREATMENT & POST-EXPOSURE PROPHYLAXISSource text for Eikon:    Further company coverage:    ((Reuters.Briefs@thomsonreuters.com;))","kind":null,"is_publish_news":null,"is_publish_highlight":null,"is_publish_live":null,"is_publish_wemedia":null,"editions":null,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.22.5","shortVersion":"4.22.5","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2432831576"}